FDA Greenlights J&J's Controversial Diabetes Drug

Law360, Los Angeles (March 29, 2013, 10:00 PM EDT) -- The U.S. Food and Drug Administration said Friday that it had approved Johnson & Johnson's Invokana, the first in a new class of diabetes drugs, less than three months after announcing concerns about possible cardiovascular and bone risks.

Invokana, which consists of the drug canagliflozin, is the first sodium-glucose co-transporter 2 inhibitor, which allows glucose to pass out of the body, that the FDA has approved. Along with greenlighting the drug, the FDA announced that it is conducting five post-marketing studies to assess the drug's cardiovascular...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.